RecruitingNCT06534814

Development and Application of an Artificial Intelligence-driven Accurate Identification Model for Gastric Cancer Lymph Node Metastasis

Hebei Medical University


Sponsor

Hebei Medical University

Enrollment

300 participants

Start Date

Jul 1, 2024

Study Type

OBSERVATIONAL

Conditions

Summary

The clinical trial titled "Development and Application of an Artificial Intelligence-Driven Accurate Identification Model for Gastric Cancer Lymph Node Metastasis" aims to enhance the detection and treatment of gastric cancer through the utilization of cutting-edge artificial intelligence (AI) technology. This study will develop an AI-driven model designed to accurately identify lymph node metastasis in patients with gastric cancer, which is crucial for staging the disease and planning effective treatment strategies. The trial will involve a multidisciplinary team of oncologists, radiologists, data scientists, and AI experts who will collaborate to create a robust and precise identification system. Participants will undergo standard diagnostic procedures, and the AI model will analyze imaging and pathological data to predict lymph node involvement. By comparing the AI model's predictions with traditional diagnostic methods, the study seeks to validate the model's accuracy and efficiency. This approach is expected to improve early detection rates, reduce diagnostic errors, and ultimately lead to better clinical outcomes for patients with gastric cancer. The successful implementation of this AI-driven model could revolutionize the current standards of care and serve as a blueprint for integrating AI technologies in other cancer diagnoses and treatments.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study develops and tests an artificial intelligence (AI) model designed to more accurately determine whether gastric (stomach) cancer has spread to nearby lymph nodes — a key factor in deciding the most appropriate surgery and treatment. Currently, this determination relies on imaging that can sometimes be inaccurate. By training the AI on large amounts of patient data, researchers hope to improve accuracy and help doctors make better treatment decisions before surgery. **You may be eligible if...** - You are 18 or older and have a confirmed diagnosis of gastric cancer (newly diagnosed or recurrent) - You have suspected or confirmed lymph node involvement - You are in reasonably good health (ECOG 0-2) - You are willing and able to provide informed consent and follow the study procedures **You may NOT be eligible if...** - You are pregnant or breastfeeding - You have severe other medical conditions that might interfere with participation - You have previously participated in another AI-driven diagnostic study for gastric cancer lymph nodes - You are unable or unwilling to comply with study follow-up requirements - You have a mental or cognitive condition that prevents you from giving informed consent Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TESTAI-Driven Identification Model for Gastric Cancer Lymph Node Metastasis (AID-GLNM)

The AI-Driven Identification Model for Gastric Cancer Lymph Node Metastasis (AID-GLNM) intervention involves the development and application of an advanced artificial intelligence (AI) system specifically designed to enhance the identification and characterization of lymph node metastasis in patients diagnosed with gastric cancer.


Locations(1)

Department of General Surgery

Shijiazhuang, Hebei, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06534814